Cancer Cells with Stem Cell-Like Phenotypes and Liver Metastasis from Colon Carcinoma

Antonia Bellizzi and Stefania Tommasi*

National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Bari, Italy

Abstract

Tumor heterogeneity contributes to the potentiality of tumors to invade and metastasize. Thus the identification of specific cells programmed to go to a specific site and establish themselves, actively proliferating and causing metastasis, could be fundamental for early diagnosis and for selective targeted therapy. Apart from gene signatures which seem to identify this tumor ability, selected cell populations with self-renewal potential have been recognized: stem cell-like cancer cells. In this paper we review recent evidence on the identification of colon cancer cells with stem cell-like properties which could have a key role in the liver metastasization. The potential clinical implication of their therapeutic eradication is also discussed.

Keywords: Stem Cell-Like Cancer cells (SCLC); Colon cancer; Metastasis

Colorectal Cancer (CRC) is the third most common cancer in men (663,000 cases, 10.0% of the total) and the second in women (570,000 cases, 9.4% of the total) worldwide. Almost 60% of the cases occur in developed regions [1] and approximately 50% of patients develop synchronous or metachronous liver metastases within 2 years from the resection of the primary tumor [2]. Most colon cancer deaths result from the metastatic spread of tumor cells to the liver and other organs [3] and for this reason it is of great significance to identify new markers capable of discriminating earlier the potential that a primary tumor has to initiate a process of liver metastasization. The standard care in patients with operable liver-confined lesions is represented by a combination of chemotherapy and surgery [4]. However, there are still some critical issues to be solved. Firstly, surgical cures are relatively rare in this setting. Secondly, how to juxtapose chemotherapy and surgery, and the duration of chemotherapy. Finally, the possibility of pre-operative chemotherapy in the case of resectable metastases [5]. This is primarily due to the fact that current chemotherapy attacks the bulk of the cancer without affecting the chemo-resistant Stem Cell-Like Cancer cells (SCLCs). These can re-grow after treatment and, eventually, develop the changes responsible for the occurrence of drug-resistance [6-8] and facilitate a persistent and aggressive tumor phenotype, with asymmetrical division [12]. On the same grounds stem cells are ideal candidates for the transformation events that occur in metastatic disease.

The majority of patients with CRC develop metastases principally within two target organs: lung and liver [13]. There are growing evidence pointing to chemokine involvement in these organ-selective metastases [14,15], and recently, a specific role of the CXCR7/chemokine axis has been demonstrated in lung compared to liver metastases [16]. However, the differential tropism from CRC to several target sites is still not well explained, including the mechanisms that drive hepatic homing. There have been a few studies performed on liver colonization by metastatic cells [17], on the modulation of pharmacological response by the liver microenvironment [18], and on the existence of peptide ligands specific for liver metastasis [19]. However, there have been no studies in this direction involving SCLCs. Indeed, current therapies for advanced CRC target molecules related to cancer progression (e.g. VEGF and EGFR) [20,21], not considering factors/cells involved in the initiation of metastasis.

In previous literature, different markers have been used to identify SCLCs and, among these, CD133, CD166 and EpCAM resulted to be well adapted to the versatility and multiplicity of the phenotypes attributed to the SCLC. CD133, originally known as AC133, is a glycoprotein also known in humans and rodents as Prominin 1 (PROM1) [22]. It is the founding member of the prominin family of pentaspan transmembrane glycoproteins. The specific functions and ligands of prominins are still unclear, but they are expressed within plasma membrane protrusions, such as epithelial microvilli and epididymal ductal epithelial stereocilia [23]. CD133 was specifically regarded as the colon cancer stem cell-surface marker and has been

Received October 31, 2012; Accepted December 21, 2012, Published December 28, 2012


Copyright: © 2013 Bellizzi A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
used to identify and isolate cancer initiating cells from human colon cancer [24]. It has been demonstrated that CD133+ cells are able to maintain themselves as well as differentiate and re-establish tumor heterogeneity upon serial transplantation in vivo [25-27].

ALCAM/CD166 is a glycoprotein that is involved in both homotypic and heterotypic (to lymphocyte cell-surface receptor CD6) adhesion and is over-expressed in several tumors [28], including colon cancer [29]. In human CRC, aberrant cell surface CD166 expression is strongly correlated with a 15 month shortened survival [29]. CD166 cell surface expression was found in the endogenous intestinal stem cell niche, suggesting that as a cell adhesion molecule, it may play an important role in maintaining the integrity of the stem cell niche, or in directing cells to the crypt base [30]. EpCAM is a glycosylated, 30–40 kDa type 1 membrane protein, which is expressed in a variety of human epithelial tissue cancers, as well as normal progenitor and stem [31]. It is expressed in all human adenocarcinomas, squamous cell carcinomas, retinoblastomas and hepatocellular carcinomas [32]. The correlation of EpCAM expression and poor survival has been described in several tumor types, including invasive breast cancer [33], urothelial carcinoma of the bladder [34], gallbladder carcinoma [35] and squamous cell carcinoma of the oesophagus [36].

Moreover, a CD44-positive subpopulation, with tumorigenic and self-renewal potential, has been selected in MCF7 breast cancer cell-engineered mammospheres [37]. CD44 is a cell surface glycoprotein involved in cell–cell interaction, cell adhesion and migration. It was identified as the cell-surface marker of breast cancer and also recently observed to be related to the distant metastasis of colon cancer [38]. CD44 exists as a large family of isoforms, produced by the alternative splicing of up to 20 exons, which generate different binding sites for the molecule [39,40]. These variant isoforms are expressed in many different organs and have been strongly linked to tumor progression behaviors in various cancers [41-43]. Expression of CD44 is widely identified in cancer stem cells in various organs, such as breast, colon, and pancreas [44-46].

Among these SCLC markers, CD133 and CD44, already validated as informative markers of stem cells in both primary tumors and xenografts, [24,25] have been identified in gene expression signatures whose genes have been shown to enhance cell migration and invasion activity from colon cancer to liver metastasis [47].

Our own study [48] evidenced a particular group of cells able to specifically metastasize to the liver which express CD133/CD44. To achieve these results, human colonosphere cultures of stem cells were obtained from fresh samples deriving from colon cancer and liver metastasis specimens under serum-free culture conditions. Phenotypical and functional characteristics of SCLCs were compared to those present in the corresponding non tumor counterpart, adjacent to the neoplastic lesion. The expression of CD133 and CD44 in our own non-selected naïve samples (Figure 1), in clones obtained after 5 months of cell selection (Figure 2) and in tissue slices of the same patient demonstrated that a CD133+/CD44+ population was present in primary CRCs and in metastatic liver tumors. Furthermore, the amount of CD133+/CD44+ SCLCs in metastatic liver tumors was greater than that in primary colorectal tumors, while CD133+/CD44- SCLCs were hardly detected in the corresponding normal colorectal tissue. These data demonstrate an enrichment of CD133+/CD44+ cells in metastatic cancers, which underlines that these cells may play a potential role in hepatic driving metastasis of CRC.

Recently, in line with this, there have been some studies addressing CD133 and CD44 co-expression as cancer stem cell antigens in colon cancer patients [49,50]. CD44/CD133 co-expression was significantly higher in colon cancers with early liver metastases compared to those without, suggesting that CD133 and CD44 protein co-expression in colon cancer may be a potential biomarker for early liver metastasization [38]. Indeed, Chen et al. demonstrated that sorted CD133+/CD44+ cells are undifferentiated, endowed with extensive self-renewal and epithelial lineage differentiation capacity in vitro, more invasive in vitro and responsible solely for liver metastasis in vivo [51].

Recently Fang et al. evaluated miRNA expression differences between colon SCLCs with the CD133+/CD44+ and CD133–/CD44– surface phenotype from the human SW1116 colon adenocarcinoma cell line, emphasizing that the difference between the two immunophenotypes was due to miRNAs closely related not only to cell cycle and cell differentiation pathways, keys to distinguish stem cells from non-stem cells, but also to signaling pathways related to metastatic behavior, such as cytoskeletal proteins and cell-matrix adhesion [52]. Moreover the combined CD133/CD44 expression seemed to be a strong indicator of worse disease-free survival and an independent risk factor for recurrence [53]. These data further confirm our findings on the presence of CD133+/CD44+ cells in all patients with liver metastasis, while only in 10% of non-metastatic patients [38]. All these data highlighted that CD133 and CD44 could be markers of metastasis-facilitating pathways through which liver tumor metastasis is jointly promoted.

Another key player in the biology of the metastatic process is represented by circulating tumor cells (CTCs) [54], and recent
observations support the hypothesis that detection of putative CD133 circulating cancer stem cells in the peripheral blood of patients affected by CRC might identify high-risk patients and could be an indicator of disease progression after apparently radical surgery [52,55]. We also found a detectable population of CTCs in 75% of metastatic colon cancer patients: 20% of CTCs showed membrane CD133+/CD44+ accumulation, supporting the premises that CD133+/CD44+ CTCs represent a sampling of the phenotypic cell types present in the primary and metastatic tumor deposits, and the possibility that circulating tumor cells consist of a combination of cells with malignant potential, stem cell characteristics and actively migrating cells that may go on to form liver metastatic foci.

**Influence of SCLCs in the Therapeutic Setting**

Interestingly, CD133 and CD44 have already been evaluated as cell surface markers of resistance to conventional therapies utilized in CRC: 5-Fluorouracil (5FU), oxaliplatin and irinotecan [56], and that 5-fluorouracil (FU) resistant spheroid clones tumor sphere (or spheroids) more resistant to the chemotherapeutic drug resistant [63,64] and tumorigenic CD133+/CD44+ colon cancer spheroids [65], suggesting that this compound can specifically target tumor-specific SCLCs by inhibiting some stemness-related signaling pathways.

**Conclusions**

The identification of SCLCs expressing CD133/CD44 as a potential marker of hepatic metastasization has importance for both diagnostic as well as therapeutic purposes. Targeting SCLC by these surface markers could be a valid approach to selectively eliminate SCLC that is able to metastasize to liver. Furthermore, these studies highlighted how the identified cell population could be responsible for the pharmacological resistance to conventional and new therapies, but it is already possible to identify the elements within it which may become reasonable targets for an effective drug therapy.

**Acknowledgements**

The authors would like to thank Dr. Caroline Oakley for language revision.

**References**


